Invion (ASX:IVX) — Material Events

ASX:IVX · 9 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 8 articles Notable 1 article Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
8
Invion Secures $2M Korean Grant, Expands Photosoft License, Raises $1.3MMedium
Invion secures $2M Korean grant, expands Photosoft license, raises $1.3M convertible notes
30 Jan 2026 ·Quarterly Activity and Appendix 4C Cash Flow Report ·85
Invion Secures Exclusive Global License for Photosoft™ Across Multiple DiseasesMedium
Invion Secures Exclusive Global License for Photosoft™ Technology Across Multiple Indications
3 Dec 2025 ·License Agreement Announcement ·85
Invion Expands Skin Cancer Trial to Basal Cell Carcinoma After Positive Safety and Efficacy SignalsMedium
Invion expands skin cancer trial to Basal Cell Carcinoma after positive safety and efficacy signals
21 Apr 2026 ·Clinical Trial Update ·85
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.

Market Mentions 3 - appeared in market wrap coverage

These are market wrap articles where Invion (ASX:IVX) was mentioned. They reflect broader market coverage, not company-specific announcements.

Healthcare Wrap - Week 21 (18 May -> 22 May) 2026
23 May 2026
Wrap
Healthcare Wrap - Week 17 (20 Apr -> 24 Apr) 2026
25 Apr 2026
Wrap
Healthcare Wrap - Week 5 (26 Jan -> 30 Jan) 2026
31 Jan 2026
Wrap